JNJ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Johnson & Johnson (JNJ) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has strong financials, recent FDA approvals, and positive analyst sentiment, the lack of significant upward momentum in technical indicators, insider selling, and cautious congressional trading activity suggest a more neutral stance. The stock is better suited for monitoring rather than immediate investment.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 31.891, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its support level (S1: 238.249), but there is no clear upward trend. Overall, technical indicators suggest caution.
FDA approval for Tecvayli and Darzalex Faspro combination therapy with strong clinical results.
Robust Q4 financial performance with revenue up 9.08% YoY and net income up 49.11% YoY.
Positive analyst sentiment with multiple price target increases and strong product pipeline expectations.
Insider selling has increased by 159.20% over the last month.
Congress trading data shows 4 sale transactions and no purchases, indicating caution.
MACD and RSI show no clear bullish momentum, and the stock is trading near support levels.
In Q4 2025, JNJ reported strong financials with revenue increasing by 9.08% YoY to $24.56 billion, net income up 49.11% YoY to $5.12 billion, and EPS up 48.23% YoY to $2.09. However, gross margin dropped slightly by 0.95% YoY to 67.79%.
Analysts have raised price targets recently, with the highest at $262 (Morgan Stanley). Ratings range from Neutral to Buy, with positive outlooks on new product cycles and strong financial performance. However, legal risks related to the talc MDL case remain a concern.
